Reference
Holleman MS, et al. Determining the Comparative Value of Pharmaceutical Risk-Sharing Policies in Non-Small Cell Lung Cancer Using Real-World Data. Value in Health 22: 322-331, No. 3, Mar 2019. Available from: URL: http://doi.org/10.1016/j.jval.2018.08.007
Rights and permissions
About this article
Cite this article
Evaluating risk-sharing policies for NSCLC therapies. PharmacoEcon Outcomes News 824, 11 (2019). https://doi.org/10.1007/s40274-019-5739-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5739-3